DM Clinical Research, a leading integrated clinical research network, is commemorating its 20th anniversary, celebrating two decades of expanding access to clinical trials and accelerating the development of innovative therapies for patients across the United States. Founded in 2006 with a vision to make clinical research more accessible and patient-centered, the organization has grown into one of the nation's premier research networks, now operating more than 35 research sites and providing access to a patient population of 1.97 million individuals across 32 therapeutic areas.
Over the past two decades, DM Clinical has enrolled more than 35,000 patients in clinical trials, contributing to the advancement of safe, life-changing therapies for patients and communities worldwide. The company partners with leading pharmaceutical, biotechnology, and healthcare organizations, as well as contract research organizations (CROs), to conduct high-quality trials while delivering strong enrollment performance, diverse patient access, and operational excellence. Its integrated operating model combines local physician relationships and patient access with centralized infrastructure, ensuring quality, speed, and consistent execution for sponsors and CRO partners.
Mohammad Millwala, Founder and CEO of DM Clinical Research, reflected on the milestone: "Reaching 20 years is incredibly meaningful to me. When I think about DM Clinical Research, I think first about the people, the employees who have poured their talent and heart into this organization, and the patients who have trusted us to be part of their healthcare journey. We've experienced so much growth and change over the past two decades, but what has never changed is our commitment to our patients and to doing meaningful work that makes a difference. I'm incredibly proud of what we've built together, and I'm even more excited about what we can accomplish in the next 20 years."
The company's 20th anniversary theme, "Champions of Clinical Research: 20 Years of Impact," reflects the teamwork, innovation, and dedication that have fueled its growth. Guided by core values—Think Forward, Find a Way, Create Impact, Own It, and Win Together—DM Clinical continues to invest in its people, expand access to research, and help bring new therapies to patients faster. This commitment to excellence has been recognized through industry honors, including the SPRIA Award for vaccine enrollment, the Excellence in Patient Centricity Award, ViE's Best Clinical Trial Network Award, and the SCRS Site Spark Award. In 2025, Millwala was also honored with the SCRS Christine K. Pierre Site Impact Award for his leadership.
As part of its mission to expand access to clinical research, DM Clinical continues to grow its presence in underserved communities, ensuring more patients have the opportunity to participate in life-changing trials. Looking ahead, the company plans continued expansion into new communities, broader therapeutic expertise, and increased investment in innovative technologies that improve patient access to clinical research. "As we celebrate this milestone, we remain focused on what's next," added Millwala. "The next chapter for DM Clinical is about expanding access to research, embracing new technologies, and ensuring more patients have the opportunity to participate in clinical trials that can change lives."
